Previous 10 | Next 10 |
NEW YORK and VIENNA, Austria, Sept. 09, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that H...
HOOKIPA Pharma (NASDAQ: HOOK ) : Q2 GAAP EPS of -$0.28 beats by $0.19 . More news on: HOOKIPA Pharma Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
NEW YORK and VIENNA, Austria, Aug. 13, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today reports its finan...
NEW YORK and VIENNA, Austria, Aug. 04, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that it...
HOOKIPA Pharma (NASDAQ: HOOK ) announces that US and Europe have issued patents covering the company’s proprietary replicating arenavirus technology. More news on: HOOKIPA Pharma Inc. Read more ...
NEW YORK and VIENNA, Austria, Aug. 03, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers, today announced that both the United States Patent and Trademark Off...
Evelo Bio Moves Ahead with EDP1815 Mid Stage Trial Evelo Biosciences Inc. ( EVLO ) announced that its lead drug candidate EDP1815 will now be a part of TACTIC-E clinical trial. The trial is designed to assess the safety and efficacy of certain experimental therapies in the preventing and...
HOOKIPA Pharma (NASDAQ: HOOK ) announces positive preliminary data from a Phase 2 clinical trial evaluating cytomegalovirus (CMV) vaccine candidate HB-101 in patients receiving a transplanted kidney from a live donor. More news on: HOOKIPA Pharma Inc., Healthcare stocks news, Stocks on...
Interim data demonstrate that HB‑101 is well tolerated HB-101 elicits T cell and B cell responses in the target population NEW YORK and VIENNA, Austria, June 22, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new cla...
NEW YORK and VIENNA, Austria, June 19, 2020 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced that Dr...
News, Short Squeeze, Breakout and More Instantly...
Director Dr. Malte Peters named Chief Executive Officer and Director Terry Coelho named Executive Vice President and Chief Financial Officer Company is conducting a review of its business operations and strategy to determine best path to create shareholder value and realize the full potential...
A look at the top 10 most actives in the United States Longeveron Inc. (LGVN) rose 69.0% to $4.8499 on volume of 46,980,986 shares Virpax Pharmaceuticals Inc. (VRPX) rose 161.5% to $3.0333 on volume of 46,199,502 shares Maxeon Solar Technologies Ltd. (MAXN) fell 0.6% to $0.2464 on volume ...
2024-07-09 09:02:05 ET Hookipa Pharma Inc (HOOK) announced stock split at a ratio of 1-for-10 on 2024-07-10 ... Full story available on KlickAnalytics.com